Biotechnology
Commented by Armin Schulz on July 9th, 2026 | 07:35 CEST
From Injection Blockbusters to an Oral Future: An Analysis of Novo Nordisk, BioNxt Solutions, and Pfizer in This Race
The weight-loss injection has fundamentally transformed the pharmaceutical industry and set in motion a business with billion-dollar potential, but this initial gold rush is over. The industry is undergoing a disruptive transformation in which more convenient oral alternatives are increasingly replacing the unpleasant injection. This development is shifting the balance of power, giving latecomers a historic opportunity while the market leaders must defend their dominance. The battle for power in obesity treatment has begun anew. Which company will take the lead in the next phase? Today, we take a closer look at Novo Nordisk, BioNxt Solutions, and Pfizer.
Read
Commented by Nico Popp on July 7th, 2026 | 07:35 CEST
Pulling the Plug on Cancer: Agios Pharmaceuticals, Revolution Medicines, and Vidac Pharma
Without health, everything else is nothing. In recent years, companies in the pharmaceutical and biotech sectors have already achieved major successes when it comes to easing the suffering of the chronically ill and of cancer patients. Progress is increasingly being made thanks to innovative platform approaches that make it possible to combine different technologies. One example is thermodynamic and metabolic platforms. We examine the latest trends and explain how investors can also benefit from innovations in biotechnology.
Read
Commented by Matthias Schomber on July 6th, 2026 | 07:00 CEST
Burry's Short Attack on Micron Technology, BioNTech's Radical Overhaul and Strategic Resources: a Still-Quiet Commodities Player!
While the AI boom continues to promise enormous profits, the first cracks are beginning to appear. High-profile investors are suddenly betting against some of Wall Street's former—and in some cases already fallen—favourites. Will Micron Technology stage a successful turnaround, or is a deeper correction still ahead? At the same time, Germany's biotech sector is undergoing a period of profound change. Cost-cutting programs worth billions of euros and sweeping strategic realignments are putting investors' conviction to the test. Away from the spotlight, a potentially transformative story is also unfolding in the commodities sector. Investors seeking early exposure to the long-term trend in industrial decarbonization may want to take a closer look at Strategic Resources. We examine three companies from three very different industries—each offering a distinct investment opportunity.
Read
Commented by Fabian Lorenz on July 2nd, 2026 | 07:25 CEST
Caution Advised with Novo Nordisk! TUI Is Making a Comeback! Globex Mining Outperforms Barrick Mining!
Caution advised with Novo Nordisk! Analysts warn that the pharmaceutical giant is heading toward a patent cliff. As a result, the company could lose billions. Without much fanfare, the stock has gained 30% in recent weeks. What do analysts say? Analysts remain bullish on TUI. The tourism group's stock is recommended as a "Buy". The easing of tensions in the Middle East and falling oil prices are fueling positive sentiment. The summer season will now be decisive. Globex Mining's stock has outperformed Barrick Mining this year. The recent correction offers an attractive entry opportunity to benefit from the commodities boom while diversifying risk.
Read
Commented by André Will-Laudien on June 29th, 2026 | 07:30 CEST
AI and M&A Frenzy in the Life Sciences Sector: Bayer, Vidac Pharma, Novo Nordisk, Evotec, and Eli Lilly
Yes, you read that correctly. Pharmaceutical companies are actively embracing artificial intelligence (AI) and, thanks to lower costs, better validation, and faster study setups, could emerge as winners of the new AI wave in the medium term. Many stocks in the life sciences sector had been overlooked by the market, but investors are now taking notice again. Eli Lilly is betting on AI and expanding its portfolio through targeted acquisitions, including the takeovers of sleep-wake specialist Centessa Pharmaceuticals and blood cancer specialist Ajax. At Evotec and Vidac Pharma, much of the focus is on cancer, while Novo Nordisk faces stiff competition from Eli Lilly's weight-loss drugs. Then came the welcome news regarding Bayer. The Supreme Court ruled that approximately 181,000 individual lawsuits alleging a lack of warning labels on packaging are no longer legally viable, as the US Environmental Protection Agency (EPA) has classified the herbicide glyphosate as safe. Lots of good news, and plenty of opportunities for active investors - we provide a few insights.
Read
Commented by Matthias Schomber on June 25th, 2026 | 07:10 CEST
Stock Market Thriller 2026: Novo Nordisk Under Pressure, Deutsche Telekom at EUR 26, and Antimony Resources on the Attack!
Created and published on behalf of Antimony Resources Corp.
The stock market is currently a world of extremes. While former high-flyer Novo Nordisk, once Europe's most valuable company, is grappling with sharp corrections and mounting competitive pressure, the established telecommunications giant Deutsche Telekom is quietly building the digital future of Germany and Europe. However, the stock is currently fighting what is likely the most important battle of the year against a critical chart level that will determine its future price trajectory. Yet the most exciting stories are often not written by mega-cap companies, but by smaller companies with significant growth potential. In this report, we take a closer look at three stocks. We begin with pharmaceutical heavyweight Novo Nordisk, then examine Deutsche Telekom's AI ambitions and the importance of its key technical price level. Finally, we turn our attention to an intriguing Canadian resource explorer that may be on the verge of a major breakout. The focus is on antimony, and the company is Antimony Resources. Sit back and discover hidden opportunities in today's market with us.
Read
Commented by Fabian Lorenz on June 24th, 2026 | 08:40 CEST
Alarm at BMW! Sell-off at BioNTech! Desert Gold Undervalued!
Alarm at BMW. First, the company shocked shareholders with a profit warning. Now, business in China has collapsed. Analysts are finally reacting by slashing their estimates and price targets. Is it time to buy now? From the perspective of GBC Research, Desert Gold is the stock to buy right now. The company is set to transition from an explorer to a gold producer this summer. Analysts see its intrinsic value well above current price levels. And what about BioNTech? The share has been trading sideways for months. The announcement of location closures has drawn heavy criticism. Shareholders are equally disillusioned. Could rival Moderna, of all companies, now bring hope to the workforce?
Read
Commented by Armin Schulz on June 24th, 2026 | 08:30 CEST
Cancer remains the hottest bet in the pharmaceutical market: Bayer, Vidac Pharma, and Pfizer are competing for the next generation of therapies
The oncology market is the most dynamic segment of the pharmaceutical industry. While global heavyweights are positioning their multibillion-dollar pipelines, a small biotech company is banking on a scientific approach that directly targets the metabolism of tumour cells. For investors, the key question is whether the future of cancer treatment will be defined by broad-based therapies, targeted antibody-drug conjugates, or precise interventions at the cellular metabolic level. The differing approaches taken by Bayer, Vidac Pharma, and Pfizer promise to set the course not only medically but also financially for the coming decade.
Read
Commented by Tarik Dede on June 24th, 2026 | 08:05 CEST
Innovation in Research: Opportunities at Vertex Pharmaceuticals, BioNxt Solutions, and BioNTech
On social media, you can find all sorts of negative comments and memes about the Pfizer Corporation. One very popular one claims that the company—founded in New York by German immigrants (Karl Pfizer and Karl Erhart)—has never cured a single disease in its 177-year history. This is at least partly true, as Pfizer—particularly for chronic, widespread conditions like high blood pressure or high cholesterol—focuses on treating symptoms rather than the underlying causes. However, it is also true that during World War II, Pfizer was the world's first and largest mass producer of penicillin. Critics level this same accusation against many pharmaceutical companies. Nevertheless, there are numerous companies working on innovative approaches to truly defeat diseases and improve people's lives. And, of course, they also aim to make a lot of money in the process. That is why we are taking a look today at the stocks of Vertex Pharmaceuticals, BioNxt Solutions, and BioNTech.
Read
Commented by Nico Popp on June 18th, 2026 | 07:35 CEST
The Secret Mechanism That Kills Cancer Cells: What Revolution Medicines and Merck & Co. Need to Learn from Vidac Pharma
There is, without exaggeration, a looming "patent cliff" of enormous scale: an estimated USD 236 billion in annual revenue losses are forcing the biopharmaceutical industry to find new paths forward. Pharma giants must replace dwindling blockbuster revenues by strategically acquiring innovative oncology platforms, as conventional cancer therapies are increasingly reaching their limits. This innovation pressure is triggering a consolidation wave in which research-driven biotech companies with protected mechanisms of action are moving into the center of potential takeover activity. In particular, intracellular and metabolic treatment approaches are rapidly gaining importance in the fight against treatment-resistant cancers. We take a look at Revolution Medicines' successes and identify the next potential high-flyer.
Read